Skip to main content

Table 1 Summary of studies included in the review

From: Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries

Author, Year Country Population/
Setting
Comparator strategiesa Data Baseline parameters Resultsa
HBsAg prevalence Cascade of Care
Screening uptake Linkage to care & Adherence to treatment
Eckman, 2011 [23] USA General population (primary care) • Screen & treat
(4 regimens)
• No screening
CEA; Hypothetical cohort 2% ns 100% adherence $29,230/QALY
(2008)
Nayagam, 2016 [22] The Gambia General population (community) • Screen & treat
• Status quo
CEA; Screening data 8.8% 68.9% 81.3% linkage,
80.9% adherence
$540/DALY
($645/LY,
$511/ QALY)
(2013)
Wong, 2011 [27] Canada Migrants (primary care) • Screen & treat
• Screen, treat & vaccinate
• Status quo (no screening)
CEA; Hypothetical cohort 4.81% 100% 90% of all eligible will receive treatment C$69,209/QALY
(2008)
Rossi, 2013 [25] Canada Newly arrived Migrants • Universal vac
• Screen & vac
• Screen & treat
• Screen, treat & vac
• No intervention
CEA; Hypothetical cohort 6.5% 70% 60% linkage,
75% eligible will have treatment
C$40,880/QALY
(2011)
Hutton, 2007 [24] USA Asian & pacific islander adults • Universal vac
• Screen & treat
• Screen, treat & ring vac
• Screen, treat & vac
• No intervention
CEA; Hypothetical cohort 10% 70% 100% will accept medical treatment $36,000/QALY
(2006)
Jazwa, 2015 [30] USA Overseas testing of refugees • Vaccination only
• Screen, vac & treat
CBA; Hypothetical cohort 6.8% 100% 60% linkage,
90% adherence
$90 M net benefit after 5 yearsb
(2012)
Veldhuijzen, 2010 [28] Holland Migrants • Screen & treat
• Status quo
CEA; Hypothetical cohort 3.35% 35% 58% linkage,
75% adherence
€8966/QALY
Rein, 2011 [26] USA Asian Migrant population
(primary care & outreach)
• Comparison of 4 screening methods CEA; Screening data 5.6–6.6% n/a n/a $40- $280 per complete screen. $609–$4657 per positive case detected
(2008)
Ruggeri, 2011 [29] Italy High risk groups • Screen & treat
• No screening
CEA; Hypothetical cohort 7% 100% 100% adherence €18,225/QALY
  1. CEA Cost-effectiveness Analysis, CBA Cost Benefit Analysis, C$ Canadian dollar, ns not specified
  2. aThe most favourable comparator strategy is highlighted in bold and reported in the results column. The year in brackets represents the year of costs, if clearly reported in the study
  3. bValue of statistical life (basecase estimated at $5 M)